Clinical trials: Head and Neck Cancer Patients
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Solid Tumors
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer. This was a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT03301896
- Testing
- LHC165, PDR001
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer
AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer
This study aims to integrate multi-omics data (genomics, transcriptomics, proteomics) from esophageal cancer patients with artificial intelligence and digital twin technology to construct personalized virtual patient models that…
- Trial name
- ESCA-DT (NCT07757022)
- Testing
- Toripalimab, Paclitaxel, Cisplatin
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC)
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer.
- Trial name
- NCT02684253
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma
Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)
This is a monocentric, non-randomized, prospective, in silico feasibility study conducted by Strasbourg Europe Cancerology Institute.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- OPPIDOM (NCT04801472)
- Testing
- Optimisation of dental implant sites protection from irradiation
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Oropharyngeal Cancer, Hypopharyngeal Cancer
Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
The purpose of this study is to evaluate the efficiency and safety of adding nimotuzumab to neoadjuvant and concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced squamous cell carcinoma of the…
- Trial name
- NCT01516996
- Testing
- docetaxel and cisplatin, IMRT, Nimotuzumab
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- The Second People's Hospital of Sichuan
Esophageal Squamous Cell Carcinoma
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with…
- Trial name
- NCT06988956
- Testing
- Nimotuzumab, Tegafur, radiotherapy
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Melanoma (Skin), Melanoma
Head and Neck Melanoma; Access to Staging and Surgical Treatment
Melanoma is a serious type of skin cancer and is the 5th most common cancer in the United Kingdom (UK). It can affect anywhere on the skin including on the head and neck. The cancer often is first noticed as an abnormal mole.
- Trial name
- NCT05900102
- Where
- United Kingdom
- Volunteers
- 86,000 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Sarcoma, Melanoma
A Study of PRT1419 in Patients With Advanced Solid Tumors
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors.
- Conditions
- Sarcoma, Melanoma, Lung Cancer, Breast Cancer
- Trial name
- NCT04837677
- Testing
- PRT1419
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Prelude Therapeutics Incorporated
Oral Cavity Squamous Cell Carcinoma
A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy based of cisplatin with sintilimab as first-line therapy for patients with advanced oral cavity squamous cell carcinoma.
- Trial name
- NCT05749042
- Testing
- Sintilimab, Radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xin-Hua Xu
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Fibrosis
PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients
Objectives: This is a feasibility study in preparation for the main multicentre randomised trial, which is anticipated to have two arms: Arm A: the current best standard of care [rehabilitation exercises] Arm B: the current best…
- Trial name
- PITSTOP (NCT03723291)
- Testing
- Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months, • Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Esophageal Squamous Cell Carcinoma (ESCC)
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal…
- Trial name
- NCT03957590
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 33 sites in China
- Volunteers
- 370 people
- Sponsor
- BeiGene
Head and Neck Neoplasms
Feasibility Testing a Decision-support Intervention for Clinical Trials
A decision-support intervention are developed for a Danish nationwide randomised controlled trial (RCT) among patients with laryngeal and pharyngeal cancer referred to curative intended radiotherapy.
- Trial name
- NCT06291610
- Testing
- Clinical trial decision support intervention
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Esophagus Cancer
The Efficacy and Safety of Caffeic Acid for Esophageal Cancer
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- CAEC (NCT03070262)
- Testing
- CA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Differentiated Thyroid Cancer, Pediatric Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- NCT05783323
- Testing
- Larotrectinib monotherapy, 131I therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should…
- Trial name
- NCT02544880
- Testing
- Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Donald T. Weed, MD, FACS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.